Insider Trading February 19, 2026

Director Jennifer L. O'Shea Increases Stake in Strategic Acquisitions (STQN) With Large Share Purchase

Ten-percent owner buys 10 million shares at $0.001 apiece; warrants and weak financial metrics highlighted in SEC filing

By Priya Menon STQN
Director Jennifer L. O'Shea Increases Stake in Strategic Acquisitions (STQN) With Large Share Purchase
STQN

Jennifer L. O'Shea, a director and 10% owner of Strategic Acquisitions INC /NV/ (STQN), purchased 10,000,000 shares of common stock on February 18, 2026, at $0.001 per share, according to a Form 4 filing. The transaction raised her direct ownership to 10,018,565 shares. The filing also notes previously issued warrants and InvestingPro data flagging valuation and financial-health concerns for the company.

Key Points

  • Director Jennifer L. O'Shea purchased 10,000,000 shares on Feb. 18, 2026 at $0.001 per share, totaling $10,000.
  • Post-transaction direct ownership is 10,018,565 shares; O'Shea also holds 18,565 warrants exercisable at $1.20 until Aug. 31, 2027.
  • InvestingPro data in the filing flag the stock as overvalued, show a ~90% six-month decline, a -3.16 beta, a $0.41M market cap, and a "WEAK" financial health rating.

Jennifer L. O'Shea, identified in a Securities and Exchange Commission Form 4 filing as a director and 10% owner of Strategic Acquisitions INC /NV/ (EXCHANGE: STQN), purchased 10,000,000 shares of the company's common stock on February 18, 2026. The shares were acquired at $0.001 each, producing a total transaction value of $10,000.

Following the purchase, O'Shea's direct holdings in the company stand at 10,018,565 shares. The filing also records that she holds 18,565 warrants issued on August 31, 2022, each exercisable for common stock at an exercise price of $1.20. Those warrants carry an expiration date of August 31, 2027 and, given the company's current trading level, are out of the money.

Market data provided in the filing indicates the stock is trading at $0.06, which, relative to the $0.001 purchase price, represents a substantial unrealized paper gain on the transaction. At the same time, InvestingPro analysis cited in the filing states the stock is currently overvalued relative to its Fair Value. InvestingPro data referenced in the filing also show the share price has declined nearly 90% over the past six months and that the stock has a beta of -3.16, suggesting it has frequently moved counter to broader-market directions.

Additional metrics included in the filing show Strategic Acquisitions' market capitalization at approximately $0.41 million and an overall financial health rating described as "WEAK" by InvestingPro. Those markers underscore the current valuation and financial-condition signals that investors considering the company or its warrants should note.


Clear summary

  • Jennifer L. O'Shea bought 10,000,000 shares of Strategic Acquisitions on Feb. 18, 2026, at $0.001 per share, spending $10,000 in total.
  • Her direct ownership after the trade is 10,018,565 shares; she also holds 18,565 warrants with a $1.20 exercise price expiring Aug. 31, 2027.
  • InvestingPro data in the filing mark the stock as overvalued relative to Fair Value, show a nearly 90% six-month decline, a -3.16 beta, a $0.41M market cap, and a "WEAK" financial health rating.

Key points

  • Insider purchase: A director and significant owner added 10,000,000 shares at a nominal price, increasing direct holdings.
  • Market markers: The stock's current trading price of $0.06 implies a paper gain versus the purchase price; valuation and volatility metrics cited by InvestingPro point to elevated risk.
  • Warrants status: 18,565 warrants owned by O'Shea are exercisable at $1.20 and expire in 2027, and are presently out of the money.

Risks and uncertainties

  • High volatility: The company's share price has fallen nearly 90% over six months and carries a negative beta (-3.16), indicating atypical and potentially counter-market swings.
  • Valuation and financial health: InvestingPro labels the stock overvalued relative to Fair Value and assigns a "WEAK" financial health rating; these raise questions about balance-sheet strength and valuation accuracy.
  • Warrants out of the money: With an exercise price of $1.20 and the stock trading substantially below that level, the warrants held are currently not economically exercisable.

Investors evaluating the filing should weigh the insider purchase against the broader valuation, volatility, and financial-health indicators disclosed. The SEC Form 4 provides the transaction details and the company's capital structure elements referenced above.

Risks

  • The stock's extreme volatility and negative beta suggest heightened market risk and atypical price movements.
  • InvestingPro's assessment of overvaluation and a "WEAK" financial-health rating point to potential balance-sheet and valuation concerns.
  • Warrants held by the insider are out of the money given the current share price relative to the $1.20 exercise price.

More from Insider Trading

Standex Director Disposes $513K in Stock as Company Posts Q2 Beat Feb 20, 2026 Sonoco Packaging Executive Disposes Small Stake as Company Outlines Multi-Year Earnings Goals Feb 20, 2026 Bank of the James President Buys $25,068 of Stock as Co-Founder Retires Feb 20, 2026 Bank of the James Director Adds $20,412 in Shares; Co-Founder Retires After Long Tenure Feb 20, 2026 Rogers Corp Director Disposes of 8,000 Shares; Stock Near Yearly High After Strong Quarter Feb 20, 2026